Qamcom is proud to contribute to an exciting project in collaboration with the Swedish Forest Agency (Skogsstyrelsen) and Spacemetric. Monitoring clear-cuts is critical for sustainable management, but traditional optical satellite methods face challenges from weather and seasonal changes. To address this, Qamcom together with Spacemetric are developing an AI-driven solution using radar satellite data for consistent and accurate forest monitoring year-round.

Testing radar hardware in the real world is logistically punishing and sometimes impossible — especially for flight and defense systems. ICX AB asked Qamcom to build a kind of virtual reality for radars: a building-sized simulator that creates over-the-air echoes for any environment the customer wants to test against, in real time.

Mabtech and Qamcom have collaborated on R&D since 2016, with the Iris and Astor platforms among the joint innovations. The EYRA platform marks a new chapter — a no-contact, automation-ready instrument built around a purpose-built confocal microscope, designed to redefine what's possible in multiplex analysis.

Mabtech is a Swedish biotech company specialising in immunoassays for research and clinical diagnostics. Their FluoroSpot, ELISpot, and FociSpot readers are used worldwide in vaccine development and disease characterisation — and making them more accurate and easier to use directly translates to faster research outcomes.

Sensrad is a spin-out product company from Qamcom's radar division, born to redefine what a radar sensor can do. Their 4D high-resolution radar technology serves vehicles, infrastructure, and surveillance — generating point clouds detailed enough to enable assistant driving, full autonomy, and complex object detection.

Mabtech is a Swedish biotech company. Founded by researchers in 1986, the Stockholm-based company is still run by researchers today and is internationally renowned for the tools it has developed for life science research, in particular in the field of immunology.

Mabtech is a leader in providing monoclonal antibodies and kits suitable for ELISpot and FluoroSpot analysis. Used by scientists worldwide to study immune responses in, for example, infectious diseases, cancers, allergies, transplantations and vaccine trials, the kits required third party readers for spot analysis. These readers lack the accuracy and precision needed in analysing spots secreted by single immune cells. Furthermore, they require calibration by the user – a step which will invariably add an element of subjectivity to the analysis and might therefore compromise the accuracy of the results.

Passionate about biomedical research and ensuring extreme accuracy in the discovery process, the Mabtech team felt that the situation could be improved.

"In order to realise our goal of fundamentally redefining spot reading technology, we needed a partner who could not only bring the technical skills we required, but who would also truly share our passion for the project. Qamcom did both, overcoming significant development challenges and delivering some brilliant enhancements to the product that even we had not thought of. Working with Qamcom, we were confident that there were no boundaries to what we could achieve together."
Christian Smedman, CTO, Mabtech

The US urban broadband market is dominated by regional players with little real competition. Breaking in required a rooftop product built on the license-free 60 GHz spectrum — and a network architecture that could keep operational cost low at scale.